CR20220119A - Formas de dosificación para bupropión enantioméricamente enriquecido o puro - Google Patents

Formas de dosificación para bupropión enantioméricamente enriquecido o puro

Info

Publication number
CR20220119A
CR20220119A CR20220119A CR20220119A CR20220119A CR 20220119 A CR20220119 A CR 20220119A CR 20220119 A CR20220119 A CR 20220119A CR 20220119 A CR20220119 A CR 20220119A CR 20220119 A CR20220119 A CR 20220119A
Authority
CR
Costa Rica
Prior art keywords
dosage forms
bupropion
enantiomerically enriched
methods
pure
Prior art date
Application number
CR20220119A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/052210 external-priority patent/WO2020061486A2/en
Priority claimed from US16/830,637 external-priority patent/US20200222339A1/en
Priority claimed from US16/907,691 external-priority patent/US11433035B2/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20220119A publication Critical patent/CR20220119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta divulgación se refiere a las formas de dosificación que contienen un bupropión enantioméricamente enriquecido o puro, tal como un exceso enantiomérico del (<em>S</em>)-bupropión, del (<em>S</em>)-bupropión enantioméricamente enriquecido o del (<em>S</em>)-bupropión enantioméricamente puro, y a los métodos de uso de estas formas de dosificación. Estas formas de dosificación se pueden administrar a los seres humanos en una cantidad reducida en comparación con la cantidad de bupropión racémico que se administraría en la misma situación
CR20220119A 2019-09-20 2020-08-18 Formas de dosificación para bupropión enantioméricamente enriquecido o puro CR20220119A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2019/052210 WO2020061486A2 (en) 2018-09-20 2019-09-20 Dosage forms and methods for enantiomerically enriched or pure bupropion
US202062971174P 2020-02-06 2020-02-06
US202062978626P 2020-02-19 2020-02-19
US202062992060P 2020-03-19 2020-03-19
US16/830,637 US20200222339A1 (en) 2018-09-20 2020-03-26 Dosage forms and methods for enantiomerically enriched or pure bupropion
US16/907,691 US11433035B2 (en) 2018-09-20 2020-06-22 Dosage forms and methods for enantiomerically enriched or pure bupropion
PCT/US2020/046755 WO2021055124A1 (en) 2019-09-20 2020-08-18 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
CR20220119A true CR20220119A (es) 2022-06-22

Family

ID=74884634

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220119A CR20220119A (es) 2019-09-20 2020-08-18 Formas de dosificación para bupropión enantioméricamente enriquecido o puro

Country Status (14)

Country Link
EP (1) EP4031121A4 (es)
JP (2) JP2022549192A (es)
KR (1) KR20220066930A (es)
CN (1) CN114423417A (es)
AU (2) AU2020349419B2 (es)
BR (1) BR112022005045A2 (es)
CA (1) CA3154718A1 (es)
CO (1) CO2022003126A2 (es)
CR (1) CR20220119A (es)
EC (1) ECSP22030119A (es)
IL (1) IL291514A (es)
MX (1) MX2022003346A (es)
PE (1) PE20221314A1 (es)
WO (1) WO2021055124A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051166A1 (en) * 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (+) -bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US20190216800A1 (en) * 2013-11-05 2019-07-18 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
BR112020017179A2 (pt) * 2018-02-23 2020-12-22 Axsome Therapeutics, Inc. Formas de dosagem e métodos para bupropiona enriquecida enantiomericamente ou pura

Also Published As

Publication number Publication date
WO2021055124A1 (en) 2021-03-25
AU2020349419A1 (en) 2022-03-24
BR112022005045A2 (pt) 2022-07-05
EP4031121A4 (en) 2022-11-30
CN114423417A (zh) 2022-04-29
MX2022003346A (es) 2022-04-11
KR20220066930A (ko) 2022-05-24
PE20221314A1 (es) 2022-09-07
EP4031121A1 (en) 2022-07-27
JP2022549192A (ja) 2022-11-24
IL291514A (en) 2022-05-01
ECSP22030119A (es) 2022-05-31
CO2022003126A2 (es) 2022-04-19
AU2024200081A1 (en) 2024-01-25
CA3154718A1 (en) 2021-03-25
AU2020349419B2 (en) 2023-11-02
JP2024059812A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX2022005380A (es) Composiciones que comprenden colina.
MX2023009281A (es) Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro.
GEP20247585B (en) Furoindazole derivatives
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2021007142A (es) Compuestos organicos.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
CR20220119A (es) Formas de dosificación para bupropión enantioméricamente enriquecido o puro
EP3818981A4 (en) SYNERGIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN
SG11201901617PA (en) Azole compound ophthalmic preparation
PH12020550549A1 (en) Compositions for preventing or treating lupus
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
PH12021500016A1 (en) Methods of reducing the risk of cardiovascular events in a subject
AU2017202335A1 (en) Hangover cure.
EA202191907A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
MX2013006332A (es) Composiciones farmaceuticas orales para uso en dislipidemias.
UA118137U (uk) Спосіб проведення аплікаційної анестезії в стоматології
UA27828U (en) Method for treating prosthetic stomatitis against the background metabolic syndrome
UA27830U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome